5 research outputs found
Brucella ovis mutant in ABC transporter protects against Brucella canis infection in mice and it is safe for dogs.
BACKGROUND/OBJECTIVES:Vaccination is the most important tool for controlling brucellosis, but currently there is no vaccine available for canine brucellosis, which is a zoonotic disease of worldwide distribution caused by Brucella canis. This study aimed to evaluate protection and immune response induced by Brucella ovis ÎabcBA (BoÎabcBA) encapsulated with alginate against the challenge with Brucella canis in mice and to assess the safety of this strain for dogs. METHODS:Intracellular growth of the vaccine strain BoÎabcBA was assessed in canine and ovine macrophages. Protection induced by BoÎabcBA against virulent Brucella canis was evaluated in the mouse model. Safety of the vaccine strain BoÎabcBA was assessed in experimentally inoculated dogs. RESULTS:Wild type B. ovis and B. canis had similar internalization and intracellular multiplication profiles in both canine and ovine macrophages. The BoÎabcBA strain had an attenuated phenotype in both canine and ovine macrophages. Immunization of BALB/c mice with alginate-encapsulated BoÎabcBA (108 CFU) induced lymphocyte proliferation, production of IL-10 and IFN-Îł, and protected against experimental challenge with B. canis. Dogs immunized with alginate-encapsulated BoÎabcBA (109 CFU) seroconverted, and had no hematologic, biochemical or clinical changes. Furthermore, BoÎabcBA was not detected by isolation or PCR performed using blood, semen, urine samples or vaginal swabs at any time point over the course of this study. BoÎabcBA was isolated from lymph nodes near to the site of inoculation in two dogs at 22 weeks post immunization. CONCLUSION:Encapsulated BoÎabcBA protected mice against experimental B. canis infection, and it is safe for dogs. Therefore, B. ovis ÎabcBA has potential as a vaccine candidate for canine brucellosis prevention
Le Cid : [tragi-comédie en 5 actes, en vers] / Corneille ; compositeurs non mentionnés, 17e ; Silvia Montfort (ChimÚne), Mona-Dol (Elvire), Monique Chaumette (l'Infante), Laurence Constant (Leonor)... [et al.], voix ; [orchestre] ; Jean Vilar, dir. scÚne
[Le Cid]Collection : Vie du théùtreBnF-Partenariats, Collection sonore - BelieveContient une table des matiÚre
FANFAN LA TULIPE / adaptation du film de CHRISTIAN-JAQUE ; Scénario de : René WHEELER et René FALLET ; Dialogues de : Henri JEANSON, Musique originale de : Maurice JARRE ; Gérard PHILIPE (Fanfan) - Daniel SORANO (Tranche-Montagne) - Georges WILSON (Fier à Bras) - J.P. MOULINOT (La Franchise) - André SCHLESSER (La Houlette) - Monique CHAUMETTE (Adeline) - Edwine MOITI (Madame de Pompadour), et avec Jean DESCHAMPS et Marcel CHEVALIER
BnF-Partenariats, Collection sonore - BelieveContient une table des matiĂšre
Second asymptomatic carotid surgery trial (ACST-2) : a randomised comparison of carotid artery stenting versus carotid endarterectomy
Background: Among asymptomatic patients with severe carotid artery stenosis but no recent stroke or transient cerebral ischaemia, either carotid artery stenting (CAS) or carotid endarterectomy (CEA) can restore patency and reduce long-term stroke risks. However, from recent national registry data, each option causes about 1% procedural risk of disabling stroke or death. Comparison of their long-term protective effects requires large-scale randomised evidence.
Methods: ACST-2 is an international multicentre randomised trial of CAS versus CEA among asymptomatic patients with severe stenosis thought to require intervention, interpreted with all other relevant trials. Patients were eligible if they had severe unilateral or bilateral carotid artery stenosis and both doctor and patient agreed that a carotid procedure should be undertaken, but they were substantially uncertain which one to choose. Patients were randomly allocated to CAS or CEA and followed up at 1 month and then annually, for a mean 5 years. Procedural events were those within 30 days of the intervention. Intention-to-treat analyses are provided. Analyses including procedural hazards use tabular methods. Analyses and meta-analyses of non-procedural strokes use Kaplan-Meier and log-rank methods. The trial is registered with the ISRCTN registry, ISRCTN21144362.
Findings: Between Jan 15, 2008, and Dec 31, 2020, 3625 patients in 130 centres were randomly allocated, 1811 to CAS and 1814 to CEA, with good compliance, good medical therapy and a mean 5 years of follow-up. Overall, 1% had disabling stroke or death procedurally (15 allocated to CAS and 18 to CEA) and 2% had non-disabling procedural stroke (48 allocated to CAS and 29 to CEA). Kaplan-Meier estimates of 5-year non-procedural stroke were 2·5% in each group for fatal or disabling stroke, and 5·3% with CAS versus 4·5% with CEA for any stroke (rate ratio [RR] 1·16, 95% CI 0·86-1·57; p=0·33). Combining RRs for any non-procedural stroke in all CAS versus CEA trials, the RR was similar in symptomatic and asymptomatic patients (overall RR 1·11, 95% CI 0·91-1·32; p=0·21).
Interpretation: Serious complications are similarly uncommon after competent CAS and CEA, and the long-term effects of these two carotid artery procedures on fatal or disabling stroke are comparable